voglibose voglibose voglibose (inn and usan, trade name voglib, marketed by mascot health series) is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. voglibose is a research product of takeda pharmaceutical company, japan's largest pharmaceutical company. vogilbose was discovered in 1981, and was first launched in japan in 1994, under the trade name basen, to improve postprandial hyperglycemia in diabetes mellitus. vogliboseclinical dataahfs/drugs.cominternational drug namesatc codea10bf03 (who) identifiers iupac name (1s,2s,3r,4s,5s)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol cas number83480-29-9 ypubchem cid444020drugbankdb04878 ychemspider392046 yuniis77p977ag8keggd01665 ychemblchembl476960 ycomptox dashboard (epa)dtxsid2021442 chemical and physical dataformulac10h21no7molar mass267.278 g·mol−13d model (jsmol)interactive image smiles oc1(o)c(nc(co)co)(o)(o)1o inchi inchi=1s/c10h21no7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18h,1-4h2/t6-,7-,8+,9-,10-/m0/s1 ykey:fzncgrzwxlxzsz-ciquzchmsa-n y (verify) postprandial hyperglycemia (pphg) is primarily due to first phase insulin secretion. alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal. there are three major drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest. efficacy a cochrane systematic review assessed the effect of alpha-glucosidase inhibitors in people with impaired glucose tolerance, impaired fasting blood glucose, elevated glycated hemoglobin a1c (hba1c). it was found that there was no conclusive evidence that voglibose compared to diet and exercise or placebo reduced incidence of diabetes mellitus type 2, improved all-cause mortality, reduced or increased risk of cardiovascular mortality, serious or non-serious adverse events, non-fatal stroke, congestive heart failure, or non-fatal myocardial infarction.